Addison's disease Medical Services in China

Addison's disease, also known as primary adrenal insufficiency, is a rare, chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone by the adrenal cortex. This deficiency arises from autoimmune destruction of the adrenal glands in approximately 80–90% of cases in developed countries—where the body’s immune system mistakenly targets and damages adrenal cortical tissue. Other causes include infections (e.g., tuberculosis, HIV-associated mycobacterial or fungal infections), bilateral adrenal hemorrhage, metastatic cancer, genetic disorders (e.g., autoimmune polyglandular syndrome type 1, adrenoleukodystrophy), and surgical removal of the adrenals. The pathogenesis centers on glucocorticoid and mineralocorticoid deficiency: cortisol regulates metabolism, immune response, stress adaptation, and blood pressure; aldosterone maintains sodium-potassium balance and intravascular volume. Without replacement, patients face life-threatening adrenal crises—marked by profound hypotension, hyponatremia, hyperkalemia, hypoglycemia, vomiting, confusion, and shock. Epidemiologically, Addison’s disease affects about 100–140 per million people globally, with an annual incidence of 4–6 new cases per million. It occurs equally across sexes and most commonly presents between ages 30–50, though it can manifest at any age—including childhood in genetic forms. Risk factors include personal or family history of autoimmune diseases (e.g., type 1 diabetes, Hashimoto’s thyroiditis, vitiligo), prior tuberculosis exposure (especially in endemic regions), HIV infection, antiphospholipid syndrome, and use of anticoagulants predisposing to adrenal hemorrhage. Quality of life is significantly impacted: fatigue, orthostatic dizziness, weight loss, gastrointestinal distress, depression, and reduced exercise tolerance are common—even with treatment. Patients require lifelong hormone replacement and vigilant self-management, including stress-dose steroid adjustment during illness or injury. Psychological burden is substantial due to unpredictability of crises, medication adherence demands, and social stigma around chronic invisible illness. Pregnancy requires specialized endocrinology oversight to prevent maternal-fetal complications. Early diagnosis remains challenging due to nonspecific, insidious symptoms—leading to delays averaging 3–6 months from symptom onset to confirmation via morning serum cortisol, ACTH, and ACTH stimulation test. With timely, individualized glucocorticoid (hydrocortisone or prednisone) and mineralocorticoid (fludrocortisone) replacement, life expectancy approaches normal, but mortality remains elevated compared to the general population—primarily due to delayed crisis recognition and suboptimal dosing.

Addison’s disease, or primary adrenal insufficiency, is a chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone due to autoimmune destruction, infection (e.g., tuberculosis), hemorrhage, or genetic causes affecting the adrenal cortex. Management requires lifelong hormone replacement, vigilant monitoring, and patient education to prevent life-threatening adrenal crises. Treatment is exclusively coordinated by the Department of Endocrinology and is fundamentally conservative—no curative surgical or ablative interventions exist for the underlying adrenal failure. However, definitive management of identifiable secondary causes (e.g., resection of an ACTH-secreting pituitary tumor in secondary adrenal insufficiency) may be considered, though this does not apply to classic primary Addison’s.

Conservative treatment forms the cornerstone of care and centers on physiological glucocorticoid and mineralocorticoid replacement. Patients must receive daily hydrocortisone (15–25 mg total, divided into two or three doses—with the largest dose upon waking and a smaller dose at noon; optional low-dose evening dose if needed for fatigue) to mimic the natural diurnal cortisol rhythm. Prednisone or dexamethasone are alternatives but less physiologic due to longer half-lives and lack of circadian alignment; thus, hydrocortisone remains first-line globally and especially preferred in China for its metabolic fidelity and lower risk of Cushingoid side effects with appropriate dosing. Fludrocortisone acetate (0.05–0.2 mg once daily) is added to replace aldosterone, with dosage titrated based on clinical assessment (orthostatic blood pressure, serum potassium, plasma renin activity), and confirmed by absence of postural hypotension and normalization of electrolytes. Sodium chloride supplementation (3–6 g/day) is frequently advised, particularly during summer months or physical exertion, to support intravascular volume and mitigate salt-wasting.

Medication adherence and stress-dosing protocols are non-negotiable components of pharmacotherapy. During intercurrent illness, injury, surgery, or fever, patients must double or triple their usual hydrocortisone dose for 2–3 days—or administer parenteral hydrocortisone (100 mg IV/IM) immediately if vomiting or altered consciousness occurs. All patients must carry a steroid emergency card and wear medical identification. Regular endocrine follow-up every 3–6 months includes assessment of weight, blood pressure (supine and standing), serum electrolytes, fasting glucose, lipid profile, bone mineral density (DEXA scan every 2–5 years), and evaluation for comorbid autoimmune conditions (e.g., thyroiditis, type 1 diabetes). Dose adjustments are guided by symptom control—not biochemical markers alone—as cortisol assays are unreliable for monitoring replacement adequacy.

Surgical treatment has no role in primary adrenal insufficiency itself. Adrenalectomy is contraindicated and would exacerbate hormonal deficiency. However, in rare cases where Addison’s results from metastatic malignancy, bilateral adrenal hemorrhage secondary to anticoagulation, or infiltrative diseases (e.g., lymphoma), surgical intervention may address the precipitating pathology—but only after endocrine stabilization and never as primary therapy for adrenal failure. Similarly, laparoscopic adrenalectomy for incidentalomas or pheochromocytoma is unrelated to Addison’s management and falls outside this indication. Thus, surgical options are strictly limited to managing coexisting or causative conditions—not the adrenal insufficiency per se.

China offers distinct advantages in the longitudinal management of Addison’s disease. First, the national healthcare system enables broad access to generic hydrocortisone and fludrocortisone at highly subsidized costs—critical for lifelong therapy. Second, integrated endocrine centers in tier-1 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital) employ standardized, evidence-based protocols aligned with Endocrine Society and Chinese Endocrine Society guidelines, ensuring consistent diagnostic workup (including ACTH stimulation testing, adrenal autoantibodies, and imaging) and therapeutic titration. Third, digital health infrastructure—including AI-assisted medication reminders, tele-endocrinology consultations, and WeChat-linked patient education platforms—enhances adherence and crisis preparedness, particularly in rural regions via tiered referral networks. Fourth, traditional Chinese medicine (TCM) is cautiously integrated as adjunctive supportive care: licensed TCM practitioners may prescribe individualized herbal formulas (e.g., Si Jun Zi Tang derivatives) to ameliorate fatigue or gastrointestinal symptoms *only* under concurrent endocrine supervision—never as steroid substitutes. Rigorous pharmacovigilance ensures herb–drug interaction screening (e.g., St. John’s wort induction of CYP3A4, which accelerates hydrocortisone metabolism).

Recovery and long-term wellness hinge on proactive self-management. Patients should maintain a written action plan detailing stress-dosing instructions, emergency contacts, and nearest hospital with ICU capability. Annual influenza and pneumococcal vaccination are strongly recommended given increased infection susceptibility. Physical activity should be encouraged but gradually intensified; sudden exhaustive exertion without dose adjustment risks crisis. Nutrition counseling emphasizes balanced macronutrients, avoidance of chronic high-sodium intake (to prevent hypertension), and calcium/vitamin D supplementation (1200 mg Ca²⁺/day, 800–2000 IU vitamin D) to counteract glucocorticoid-induced bone loss. Psychological support is integral—depression and anxiety prevalence exceeds 30% in Addison’s cohorts—and cognitive behavioral therapy (CBT) is increasingly available through hospital-based mental health endocrine liaison services in major Chinese cities. Pregnancy requires preconception counseling and trimester-specific hydrocortisone escalation (up to 30 mg/day in third trimester); obstetric-endocrine co-management is standard in tertiary centers. With strict adherence, regular monitoring, and timely crisis response, life expectancy approaches that of the general population, and quality of life is excellent. Ultimately, successful treatment rests not on technological innovation alone, but on the sustained therapeutic alliance between patient, endocrinologist, and multidisciplinary support systems—principles deeply embedded in China’s patient-centered, protocol-driven endocrine care model.